Gazyva (obinutuzumab) received its initial FDA approval on November 1, 2013, for the treatment of chronic lymphocytic leukemia. Subsequently, it received another important approval on February 26, 2016, for certain people with previously treated follicular lymphoma.
Gazyva is a prescription medicine used in oncology to treat specific types of blood cancers. Its approval timeline reflects its development and expanded use for various patient populations, providing targeted therapeutic options.
Here is a summary of Gazyva's key FDA approval dates for its different indications:
| Date | Indication |
|---|---|
| November 1, 2013 | Chronic Lymphocytic Leukemia (CLL) |
| February 26, 2016 | Follicular Lymphoma (FL) (for certain people with previously treated FL) |
These distinct approvals mark significant milestones in making Gazyva available to patients battling these challenging conditions. The first approval in 2013 established Gazyva's role in CLL, while the 2016 approval broadened its utility to include a specific group of individuals with previously treated follicular lymphoma.
